Related Experiment Video

Updated: May 16, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Lymphocyte-polarized DC1s: Effective inducers of tumor-specific CTLs

Erik Berk1, Pawel Kalinski

  • 1Department of Sugery; University of Pittsburgh; Pittsburgh, PA USA.

Oncoimmunology
|December 18, 2012
PubMed

Insights

Activated lymphocytes enhance dendritic cell (DC) function by secreting cytokines, leading to Type-1-polarized DCs (DC1s). These enhanced DC1s exhibit improved interleukin-12 (IL-12p70) and CXCL10 secretion and boost CTL-inducing activity, offering a feasible clinical approach.

Area of Science:

  • Immunology
  • Cell Biology
  • Biotechnology

Background:

  • Activated lymphocytes produce cytokines like tumor necrosis factor α and interferon γ.
  • These cytokines can polarize dendritic cells (DCs) towards a Type-1 phenotype (DC1s).
  • DC1s are known for their potential in immunotherapy due to their immune-stimulating properties.

Purpose of the Study:

  • To investigate the effects of activated lymphocytes on dendritic cell (DC) immunogenic properties.
  • To determine if lymphocyte-induced DC polarization enhances DC function and therapeutic potential.
  • To assess the feasibility of using autologous lymphocytes for DC enhancement in a clinical setting.

Main Methods:

  • Co-culturing activated lymphocytes with dendritic cells (DCs).
  • Measuring cytokine secretion (e.g., IL-12p70, CXCL10) from polarized DCs.
  • Assessing the CTL-inducing activity of lymphocyte-polarized DCs.

Main Results:

  • Activated lymphocytes induced Type-1-polarized DCs (DC1s).
  • Lymphocyte-polarized DC1s secreted significantly higher levels of IL-12p70 and CXCL10.
  • Enhanced DC1s demonstrated superior CTL-inducing activity compared to control DCs.

Conclusions:

  • Autologous lymphocytes can effectively enhance the immunogenic properties of DCs.
  • This lymphocyte-mediated DC polarization is a low-cost and clinically compatible process.
  • The enhanced DCs hold promise for improving cancer immunotherapy strategies.

More Related Videos

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes11:48

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.